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ABSTRACT 
Objective: The present study's objective is to conduct a comparative bioavailability study with a special emphasis on the test product's 
bioequivalence using a standard reference product as a comparator. 
Methods: Before initiating the bioequivalence study, the plasma sample analysis method was developed and validated by using LC-MS/MS method. 
The entire study was conducted as a single-dose crossover randomized bioequivalence study with open-label, two treatment, two-period, and two 
sequences on 24 healthy volunteers under fasting condition. With proper informed consent process the oral dose of the Reference product (R) or 
Test product (T) was administered on healthy volunteers at 0 h during each period of the study. After the drug's oral administration, a certain 
quantity of blood sample was collected, and the plasma sample was separated using a cold centrifuge. The plasma samples were analysed by using 
the validated LC-MS/MS method. The pharmacokinetic parameters, statistical data and ANOVA of the test and reference product were evaluated.  
Results: The Cmax, Auc0-t, AUC0-∞ and tmax of the test product were found to be 6.29 ng/ml, 117.0 ng. h/ml, 161.67 ng. h/ml and 3.33 h. 
respectively. And the Cmax, Auc0-t, AUC0-∞ and tmax of reference product were found 6.59 ng/ml, 123.21 ng. h./ml, 172.20 ng. h/ml and 3.38 h 
respectively. Relative bioavailability was found 94.96%. The overall results show that the 90% confidence intervals (Log-Transformed and 
Untransformed) for Cmax, AUC0-t and AUC0-∞ for Azelnidipine were within the acceptable limit of 80%-125%. 
Conclusion: The entire study's conclusion can be drawn as the test product was bioequivalence with the reference product's comparator.  
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INTRODUCTION 
Bioavailability and bioequivalence study are some of the most 
important criteria for the drug approval process from the 
perspective of the current regulatory status. Recent advancements 
in drug formulation technology provided us various novel 
formulations based on old generic drugs. But most of the 
formulation is found unsatisfactory in terms of bioavailability. 
The drug's bioavailability should be monitored for the new formulation 
to understand the various pk parameters comparable or not. 
Here we have conducted a thorough bioequivalence study of the 
new formulation of old generic drugs Azelnidipine. 
Azelnidipine,((±)-(3)-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-
2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridine-
dicarboxylate; CS-905), is a third generation, long-acting 
dihydropyridine calcium antagonist [1]. 
The dihydropyridine calcium antagonists have two methyl groups 
[2] and two enantiomers (R-(-)-and S-(+)-enantiomers [3]. 
A novel drug, Azelnidipine, works by inhibiting both L and T-type 
calcium channels. Azelnidipine is lipophilic and highly vascular selective. 
The drug doesn't cause reflex tachycardia, and its antihypertensive 
actions appear to be the same as that of Nifedipine [4, 5]. 
Like Benidipne, Azelnidipne, too, has shown both high anti-
inflammatory and anti-oxidative properties. Azelnidipine has 
demonstrated the ability to inhibit inflammatory interleukins, 
cytokines and tumor necrosis factor, and a certain amount of free 
radical scavenging property. By virtue of this ability, Azelnidipine 
inhibits the inflammatory mediators and has shown to be effective in 
treating atherosclerosis, caused by damage of endothelial cells by all 
inflammatory interleukins, cytokines, tumor necrosis factors and 
monocytes, etc. [6, 7]. 
Under its anti-inflammatory properties, Azelnidipine has lower 
glomerular pressure (dilation of afferent and efferent arteries and 
arterioles) and reduces urinary albumin excretion [8-10]. 
Comparative pharmacokinetics needs to quantify the drug 
(Azelnidipine) in human plasma samples. Literature survey reveals 
that UPLC, HPLC and LC-MS/MS methods have been employed to 
determine Azelnidipine alone or in combination with other drugs. 
Some of these earlier reported studies were found to be tedious, 
time-consuming and less cost-effective. The plasma extraction 
technique used in the previous studies was also not found to be cost-
effective, and the total run time was found lengthy. Therefore, in the 
present study, efforts were made to develop and validate a 
bioanalytical method for simultaneous Azelnidipine estimation in 
human plasma by LC-MS/MS to analyze plasma samples obtained 
from the comparative pharmacokinetic studies on healthy human 
volunteers under the framework of bioequivalence study. Efforts 
were also made to use cost-effective and straightforward extraction 
techniques [11-13]. 
A pharmacokinetic study was conducted on Chinese volunteers 
using the LC-MS method. But the bioequivalence study was not 
conducted with all required parameters [14]. 
Further investigation finds many clinical studies were conducted on 
various groups of patients with a single or combination of Azelnidipine 
with other drugs. But pharmacokinetic studies of a single molecule with 
the bioequivalence study were not investigated with the detailed 
procedure. Few pharmacokinetic studies were traced with combination 
drugs. Instead of these, a single-molecule pharmacokinetic study with 
proper bioequivalence study according to standard regulatory 
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guidelines was investigated by us only. So the manuscript will initiate a 
proper procedure to help other contract research organizations and 
pharmaceutical companies to perform bioequivalence study of 
Azelnidipine or another same type of drugs [15, 16]. 
MATERIALS AND METHODS 
Materials 
Test sample Azelnidipine Tablet contains Azelnidipine 16 mg was 
manufactured and gifted by Akums Drugs And Pharmaceuticals, Plot 
No-19,20 and 21, Sec-6A, IIE, Ranipur, Haridwar (India). Reference 
Marketed samples of Calblock Tablet containing Azelnidipine 16 mg 
manufactured by Daiichi-Sankyo Co. Ltd were purchased from the 
local market. 
Selection of volunteers 
Selection of study population 
The general screening was conducted after the volunteers provided 
written consent on an IEC-approved 'Informed Consent for 
Screening' form. Demographic information such as sex, complete 
age, height and weight, BMI, diet, history of tobacco use, intake of 
abusive/recreational substances, alcohol intake, history of blood 
donation, and history of involvement in a drug research study. 
Health history, including related past surgical/medical history, 
food/drug/other allergy histories, family history, and past 
prescription history in the last 90 d. recording vital signs such as 
blood pressure, pulse, temperature, and respiration, as well as 
general diagnosis, physical, and structural assessment, are all part of 
the medical test. Heart rate, rhythm, and relevant findings are 
assessed using a 12-lead ECG. X-ray of the chest (PA view); 
Parameter investigation in the laboratory, including Erythrocyte 
count, platelet count, hemoglobin, Hematocrit, leucocyte count, ESR, 
and differential leucocyte count are all part of a complete blood 
count. Grouping of blood, Hepatic profile–SGOT, SGPT, GGT, Alk. 
Biochemistry–blood sugar (fasting), triglycerides and cholesterol, 
Phosphatase and Bilirubin, Renal profile–creatinine, BUN, calcium, 
electrolytes such as sodium, potassium, and chlorides, and infectious 
diseases–HIV, HbsAg, and HCV, as well as a regular urine 
examination. 
No clinically significant abnormalities in ECGs, chest X-ray (PA view) 
were reported in subjects who were included in the study. 
Additionally, serological tests (HIV, Hepatitis B and C, HCV) were 
negative. The volunteers with laboratory values within normal limits 
or clinically non-significant values were called one day before the 
study for study informed consent form presentation. Only those 
volunteers who signed the study informed consent form were checked 
in for the study on the day of check-in (one day before dosing). 
All the volunteers were found negative for a urine test for drugs of 
abuse test and breath alcohol test [Cocaine, Amphetamines, 
Marijuana, Morphine, Barbiturates, and Benzodiazepine]. Hence all 
24 fit and consenting volunteers fulfilling inclusion/exclusion 
criteria were enrolled in the study. 
Volunteers were given the rank orders based on their reporting time 
to the facility on pre-study day. Based on their rank orders and 
compliance to the protocol requirements, subject numbers were 
allotted serially. 
All inclusion and exclusion criteria for the volunteers were selected 
as per standard guidelines [17]. 
Inclusion Criteria 
As per inclusion criteria, the volunteers were included based on 
different criteria like the healthy adult human male volunteers age 
within 18 y to 45 y, weight not less than 50 kg and normal BMI within 
18.50 kg/m2 to 24.99 kg/m2. Participate in the study willing to provide 
written Informed Consent. After that normal heart rate and blood 
pressure as measured after resting supine for 3 min. Absence of 
disease markers of Syphilis, HIV 1 and HIV 2 and Hepatitis B. The 
volunteer must be a non-smoker. Volunteers' availability for the entire 
study duration, as well as their willingness to follow protocol 
guidelines, written informed consent is proof of this. 
Exclusion criteria 
As per exclusion criteria, the volunteers were excluded based on 
different criteria like History or presence of significant hepatic, 
immunologic, dermatologic, neurological, pulmonary, hematological, 
gastrointestinal, endocrine, cardiovascular, renal, psychiatric 
diseases, alcohol dependence and drug abuse during the past time. 
Found positive in breath alcohol test on the day of check-in. History 
of Asthma, urticarial, duodenal ulcer, peptic ulcer and Jaundice in 
the last 6 mo or disorder of bleeding. 
One unit or 350 ml blood loss within 56 d before the start of the 
study. Volunteers who had previously participated in a clinical study 
during the previous 90 d prior to the start of this study.  
Refuse to fast for at least 10 h before and 4 h after drug 
administration. And refuse to refrain from drinking fluids for at least 
1 h before and after taking the drug. Hypersensitivity to Azelnidipine 
and other related or un-related classes of drugs. 
Study design 
A randomized, open-label, two treatment, two-period, two sequences, 
single-dose, crossover bioequivalence study was conducted under 
fasting condition on 24 healthy, adult, human, male volunteers.  
To evaluate the comparative Bioavailability study of a single dose of 
Azelnidipine Tablet containing Azelnidipine 16 mg manufactured by 
an Akums Drugs And Pharmaceuticals, Plot No-19,20 and 21, Sec-6A, 
IIE, Ranipur, Haridwar (India) comparing with marketed samples of 
Calblock Tablet containing Azelnidipine 16 mg manufactured by 
Daiichi-Sankyo Co., Ltd. India in healthy, adult, human volunteers 
under fasting condition. 
Monitoring the safety and tolerability of a single dose of 
Azelnidipine Tablet 16 mg when administered in healthy adult 
human volunteers. 
Diagnosis and foremost criteria for inclusion 
Healthy human volunteers within the age range of 18 to 45 y with 
body mass index (BMI) of 18.50 kg/m2 to 24.99 kg/m2 having an 
absence of significant disease or laboratory evaluation or clinically 
significant laboratory values or medical history or physical 
examination during the screening and complying with inclusion and 
exclusion criteria were included. 
Criteria for evaluation 
Efficacy 
The 90 % confidence interval for Cmax, AUC0-t, AUC0-∞ of 
Azelnidipine will form the basis for concluding the equivalence of 
Azelnidipine in product R and T. If the confidence intervals are 
entirely included in the range of 80 %–125 % for AUC0-t, AUC0-∞, 
Cmax, log-transformed then the treatments will be claimed to be 
bioequivalence. 
Statistical methods 
The log-transformed pharmacokinetics (Cmax, AUC0-t and AUC0-
∞.) were analyzed using an ANOVA model and calculated 90% 
confidence interval for the ratio of both the products averages 
(geometric means) of Cmax, AUC0-t and AUC0-∞. Ratios of mean 
AUC0-t to mean AUC0-∞ for test and reference are expressed in 
percentage, and power test is performed using SAS® version 9.1.3. 
Ethical conduct of the study 
Independent ethics committee 
This protocol and corresponding informed consent form (ICF) to be 
used to obtain written informed consent of study subjects were 
reviewed by the HURIP Independent Bioethics Committee, Kolkata, 
West Bengal, India [CDSCO Registration No.: ECR/103/ 
Indt/WB/2013/RR-19]. And volunteers were not be enrolled on the 
study until the IEC approved the protocol and the ICF. 
This study was conducted in accordance with the principles of the 
Declaration of Helsinki, 'ICH GCP', ICMR Guidelines, 'Indian GCP', and 
"Schedule Y" of the Indian Drugs and Cosmetics Act. 
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Written informed consent 
The Principal Investigator or designated study personnel informed 
the volunteers (vernacular language understandable by the subject) 
before initiating the study through an oral presentation regarding 
the purpose, procedures to be carried out, investigational products, 
potential hazards and rights of the study subjects. The volunteers 
were required to understand and sign the ICF prior to check-in for 
the study in the first period, and the signed ICF was filed in the 
respective study file. 
Overall study design and plan–description 
The study design was a randomized, open-label, two treatment, two 
periods, two sequences, single-dose, and crossover bioequivalence 
study under fasting conditions. It was using 24 healthy, adult, 
human, male volunteers. 
Treatments administered 
During each time, an oral dose of the Reference product (R) or Test 
product (T) was provided with 240 ml of room temperature water at 0 
h. The dosing end time was reported in raw data forms under the 
supervision of the Medical Officer and according to the randomization 
plan. In subsequent times, volunteers will undergo the alternative 
'treatment,' ensuring that each participant has undergone both the 
'treatments' evaluation and reference at the conclusion of the study. 
Method of assigning subjects to treatment groups 
According to the randomization schedule, the volunteers were 
assigned to the intake either test or reference product. The 
volunteer number was allocated as per the rank order of the 
subject's reporting time to the clinical facility. 
Drug concentration measurements 
The concentration of Azelnidipine was measured in plasma samples 
of the volunteers. The blood samples were collected (as per 
protocol) during the study at sampling hours at pre-dose and 0.50 h, 
1 h, 1.50 h, 2 h, 2.50 h, 3 h, 4 h, 6 h, 9 h, 12 h, 24 h, 48 h, 72 h and 96 
h post-dose. Samples were collected through an indwelling cannula 
placed in a forearm vein. The pre-dose samples were collected 
within 1 h before drug dosing.  
Blood samples were collected in a 5 ml K2EDTA vial at the specified 
time. All the blood samples for a particular sample time point were 
centrifuged under refrigeration at 3500 ± 20 rpm and 4 °C ± 1 °C for 
10 min. The resulting plasma was separated and stored in suitably 
labeled polypropylene tubes at–20 °C ± 5 °C for pending assay.  
A total of 720 samples of Period-I and Period-II were transferred to 
the Bioanalytical section. The investigational products were 
administered in fasting conditions, and no food was served till 4 h 
post-dose. No fluid, except 240 ml drinking water administered with 
the investigational products, was allowed from 1 h pre-dose and 2 h 
post-dose. The investigational products were administered to the 
volunteers while in the sitting posture. Volunteers were instructed to 
remain seated or be ambulatory for the first two hours following the 
drug administration. During this interval, under supervision, 
volunteers were permitted to leave the bed for brief periods, e. g. to 
use the washroom facilities. Then volunteers were allowed to engage 
only in normal activities while avoiding severe physical exertion. 
Restrictions 
Prior to dosing and during the study, all participants were advised to 
abstain from alcohol and xanthine-containing foods and beverages 
such as cold drinks, cigarettes, tobacco products, tea, coffee and 
chocolates for at least 48 h. Before receiving any medicine, volunteers 
were also advised to refrain from eating an unusual diet for whatever 
cause, such as a low sodium diet, for 2 w prior to receiving any 
medication and for the duration of their participation in the study. 
Prior and concomitant therapy 
Receipt of any other OTC drugs or prescription drugs within 2 w 
prior to receiving the first dose of study medication or repeated use 
of drugs within the last 4 w was an exclusion criterion. Further, the 
volunteers were not supposed to consume any medicines during the 
conduct of the study. Forty-four subjects who checked in the study 
confirmed that they did not consume any medication within the 2 w 
of the start of the first period or during the study 
Bioanalytics and data processing 
A validated LC-MS/MS method was established for the estimation of 
Azelnidipine in human plasma. During the estimation of 
Azelnidipine in human plasma, quality control samples were 
distributed throughout each study sample batch [18, 19]. 
Samples from each subject were analyzed on the same standard 
curve. Samples with drug concentrations more significant than the 
upper limit of the validated range of the analysis would be diluted 
with the appropriate drug-free biological matrix and reanalyzed as 
per the method validation report. 
The analysts concerned were blinded concerning the randomization 
code, and as a result, to the order of administration of the study 
medication. 
Method development and validation 
Accurate, sensitive, rapid, precise, and simple bioanalytical method 
development and validation were done of Azelnidipine in the human 
plasma using LC-ESI-MS/MS. The method was developed by gradient 
conditions using a 0.1% Formic Acid in Acetonitrile (Pump A) and 
Milli-Q water with 10 mmol Ammonium acetate (Pump B) mobile 
phase with a flow rate of 0.5 ml/min. The Analyte and IS (Metoprolol) 
were separated using a C18 Phenomenex (50x3 mm, 5µ) column. The 
chromatographic run time was 7.0 min. The analyte and IS extracted 
from plasma by simple protein precipitation technique. The LOD and 
LLOQ were found to be 0.53125 ng/ml and 1.0625 ng/ml, respectively. 
The calibration concentrations were 1.06 ng/ml, 2.13 ng/ml, 4.25 
ng/ml, 8.5 ng/ml, 17 ng/ml, 34 ng/ml, and 68 ng/ml. The LQC, MQC 
and HQC were 3.19 ng/ml, 25.50 ng/ml, 51 ng/ml respectively. The 
validation parameters like inter-day, intra-day and stability studies 
were found within the range, as mentioned by USFDA [20] and EMA 
[21] guidelines, the results are given in table 2 and table 3. The 
extraction recovery of the drug from plasma was high.  
Appropriateness of measurements 
The plasma samples of volunteers were analyzed by a validated LC-
MS/MS method. The limit of quantification of 1.06 ng/ml for 
Azelnidipine to quantify the analyte from the plasma samples 
collected up to 96 h after drug administration. The linearity range of 
1.06 ng/ml to 68 ng/ml for Azelnidipine was enough to quantify the 
expected concentration range of Azelnidipine from volunteer plasma 
with the proposed dose of 16 mg of Azelnidipine. 
Statistical and analytical plans 
Following were the plans for statistical analysis 
We used SAS® system version 9.1.3 Analysis of Variance [ANOVA] to 
estimate pharmacokinetic parameters and its Statistical analysis for 
log-transformed pharmacokinetic parameters [Cmax, AUC0-t and AUC0-
∞] was performed. Ratio and 90% Confidence Interval for proportion 
and power for log-transformed pharmacokinetic parameters–Cmax, 
AUC0-t and AUC0-∞-was calculated. The confidence intervals are 
entirely included in the range of 80%–125 % for AUC0-t, AUC0-∞ and 
Cmax log-transformed then the treatments were claimed to be 
bioequivalence. 
RESULTS 
Demographic and other baseline characteristics 
The mean±SD of age, height, weight and BMI values for regular 
healthy human volunteers recruited in the study and those analyzed 
demographic data is summarized in table 1. 
Interday and Intraday accuracy and precision 
The Interday and Intraday; accuracy and precision of Azelnidipine 
and IS were tested and the results in table 2 demonstrated that the 
evolved approach was reproducible and accurate. 
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Table 1: Demographic data (24 Volunteers) 
 Age (Y) Height (cm) Weight (kg) BMI (kg/m2) 
mean±SD 33.08±6.88 164.08±5.79 57.75±6.41 21.43±1.85 
Maximum 42 175 72 24.77 
Minimum 22 154 51 18.61 
n= 24 volunteers, mean±SD. 
 
Table 2: Inter-day and Intraday accuracy and precision for Azelnidipine 
 Inter-day accuracy and precision (Between run) Intraday accuracy and precision (Within run) 
QC Samples Mean SD C. V. % Accuracy Mean SD C. V. % Accuracy 
LLOQ 1.06 ng/ml 1.102 0.098 8.853 103.718 1.022 0.060 5.887 96.188 
LQC 3.19 ng/ml 3.188 0.294 9.237 100.016 3.384 0.112 3.308 106.165 
MQC 25.50 ng/ml 25.147 2.062 8.200 98.617 24.746 0.798 3.225 97.043 
HQC 51.00 ng/ml 49.272 4.662 9.461 96.612 46.874 2.023 4.315 91.910 
 
Stability studies  
The various stability studies were conducted with freshly prepared 
QC concentrations of various concentrations, the results are given 
below table 3. 
Summary data for subjects included in the final analysis 
The mean pharmacokinetic parameters estimated for both the 
reference and test formulations of Azelnidipine under fasting 
conditions are as follows in table 4: 
 
Table 3: Stability of different QC standards in the different storing condition of Azelnidipine 
Stability studies QC samples (ng/ml) Mean SD C. V. % 
Benchtop Stability 
(24 h) 
LQC 3.19 2.93 0.12 3.99 
MQC 25.50 25.39 0.41 1.61 
HQC 51.00 51.51 0.96 1.86 
Autosampler Stability 
(24 h) 
LQC 3.19 3.13 0.09 3.00 
MQC 25.50 26.29 0.48 1.84 
HQC 51.00 52.28 1.13 2.16 
Freeze-thaw Stability 
(3 Cycles) 
LQC 3.19 2.90 0.08 2.84 
MQC 25.50 24.01 0.42 1.76 
HQC 51.00 49.39 1.92 3.88 
Short term Stability 
(24 h) 
LQC 3.19 3.04 0.04 1.37 
MQC 25.50 24.07 0.36 1.49 
HQC 51.00 45.28 1.05 2.33 
Long term Stability 
(30 d) 
LQC 3.19 3.03 0.10 3.29 
MQC 25.50 23.33 0.25 1.09 
HQC 51.00 58.90 3.20 6.54 
 
Table 4: Pharmacokinetic parameters in 24 volunteers with the test and reference formulation 
Pharmacokinetic parameters Reference formulation (R) Test formulation (T) 
Cmax (ng/ml) 
 
Mean 6.59 Mean 6.29 
± SD.  0.42 ± SD.  0.53 
tmax (h) Mean 3.38 Mean 3.33 
± SD.  0.49 ± SD.  0.48 
AUC 0-t (ng. h/ml) Mean 123.21 Mean 117.00 
± SD.  12. O5 ± SD.  10.64 
AUC 0-∞ (ng. h/ml) Mean 172.20 Mean 161.67 
± SD.  27.36 ± SD.  14.70 
kel (h-1) Mean 0.032 Mean 0.032 
± SD.  0.003 ± SD.  0.002 
t1/2 (h) 
 
Relative bioavailability (%) 
Mean 22.02 Mean 21.61 
± SD.  3.15 
100 % 
± SD.  1.40 
94.96% 
n= 24 volunteers, mean±SD. 
 
Table 5: 90% confidence interval 
 Ln transformed 
Cmax 0.95 to 0.99 
AUC0–t 0.98 to 1.00 
AUC0–∞ 0.97 to 1.00 
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Fig. 1: Mean plasma concentration of test Vs reference preparation of azelnidipine 16 mg tablet 
  
ANOVA summary 90% 
Cmax: The ANOVA results for untransformed and log-transformed 
data of Cmax show that the parameters like Subject, Sequence, 
period and Treatment are not statistically significant at 5%o level in 
both untransformed and log-transformed data. 
The 90% confidence interval for the ratio (Test/Reference) of geometric 
means, based on the log-transformed data for Cmax, was 95.46 % to 
99.85 % relative to Test preparation with Reference preparation. 
AUC0-t: ANOVA results for untransformed and log-transformed data 
of AUC0-t show that the parameters like Subject, Sequence, period 
and Treatment are not statistically significant at 5% level in both in 
transformed and log-transformed data. 
The 90% confidence interval for the ratio (Test/Reference) of 
geometric means, based on the log-transformed data for AUC0-t was 
found to be 97% to 100.17% relative to Test Preparation with 
Reference preparation. 
AUC0-∞: The results of ANOVA for untransformed and log-
transformed data of AUC0-∞ show that the parameters like Subject, 
Sequence, Period and Treatment are not statistically significant at 
5% level in both untransformed and log-transformed data. 
The 90% confidence interval for the ratio (Test/Reference) of 
geometric means, based on the log-transformed data for AUC0-∞ was 
found to be 97.86% to 100.06 % relative to Test Preparation with 
Reference Preparation. 
Tmax: The ANOVA results of Tmax data for the parameters like 
Subject, Sequence, Period and Treatment are not statistically 
significant at the 5% level. 
Kel.: The results of ANOVA of Kel. data for the parameters like 
Subject, Sequence, Period and Treatment are not statistically 
significant at the 5% level. 
Thalf: The results of ANOVA of Thalf data for the parameters like 
Subject. Sequence, Period and Treatment are not statistically 
significant at the 5% level. 
The geometric mean has been calculated as the antilog (or 
exponential) of the least-square means of the log-transformed data. 
Application of paired t-test that the Cmax (Untransformed data) for 
Test preparation and Reference preparation is not statistically 
significant at the 5% level and P-value: 0.070. Both the preparations 
are similar effects on the body. 
DISCUSSION 
It was not possible to blind the appearance of the products so; it was 
an open-labeled study. The analysts were blind to the sequence of 
administration of the reference and test product to the individual 
subjects. 
The order of receiving treatment was randomized to avoid bias in 
the allocation of sequence to the subjects. 
There were two treatments: One product was the test product, while 
the innovator product as the reference product. The subjects served 
as their control, the study being a crossover. 
There were two treatments, the trial design was two sequences, two 
periods. The effect of period and sequence on primary efficacy 
criteria were analyzed by ANOVA. 
Healthy, adult, human participants were chosen to minimise 
variability in the control factors and biomedical experimentation, 
which could influence the assessment and comparison of primary 
efficacy factors. 
The number of volunteers in the sample was calculated based on the 
variability of pharmacokinetic data available in the literature and 
was determined to be adequate to differentiate the bioavailability 
patterns of the products under study. 
A total of 24 volunteers were enrolled in order to have the 
completed subject data set. All 24 volunteers enrolled completed the 
study. The plasma samples of the first 24 completed volunteers were 
analyzed for Azelnidipine concentration level and utilized the data 
for pharmacokinetic and statistical evaluations. 
The pharmacokinetic parameters found in this analysis are consistent 
with those found in the published literature. Normal equations were 
used to determine bioequivalence. The 90% confidence intervals (Log-
Transformed) for Cmax, AUC0-t and AUC0-∞ for Azelnidipine were 
within the usually acceptable limit 80%-125 %. 
Developed and validated plasma samples of analysis of Azelnidipine 
by using the technique of LC-ESI-MS. The method was applied to 
determine various pharmacokinetic parameters. The results show 
Peak plasma concentration in Chinese volunteers Cmax was found 
8.66±1.15 ng/ml. The LLOQ was 0.20 ng/ml. We have a plasma 
concentration of Azelnidipine 29 ng/ml. The LLOQ was found to be 
1.06 ng/ml. The entire result is comparable with that of the result 
found in the literature [14].  
Determined Azelnidipine in human plasma by liquid 
chromatography-electrospray ionization-mass spectrometry. The 
LLOQ was 0.05 ng/ml. The Cmax of the drug was found to be around 
6.79 ng/ml. In addition, some literature was also found in 
combination drug analysis for Azelnidipine. The results of those 
combination drugs were comparable with our results [22]. 
CONCLUSION 
Both formulations are well-tolerated following a single dose 
administration of the investigational product. No clinical severe 
adverse events causing dropouts, hospitalization, disability, or 
death, of the subjects, were encountered. So, the test product is 
bioequivalence to the reference product of Azelnidipine 16 mg. No 
occurrence of adverse events during the study. 
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